NCT05767346Phase 3Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-02-28Actual

Enrollment · participants175Actual

Source updated2026-06-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-20 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Change in ~~peak~~ ~~oxygen~~ ~~uptake~~ (pVO2) by ~~cardiopulmonary~~ ~~exercise~~ ~~testing~~ (CPET)

+ After

Measure: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)

Check registry source

Study details

Conditions studied

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Treatments or interventions studied

Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Drug
Placebo to match aficamtenDrug
Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)Drug
Placebo to match metoprolol succinateDrug

Primary outcomes · main study measures

Read the study measures

measure: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET); description: Effect of aficamten compared with metoprolol succinate on exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Exercise capacity was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.; timeFrame: Baseline to Week 24

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history